A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 [panobinostat] when administered in combination with oral lenalidomide and dexamethasone in adult patients with multiple myeloma.
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2018
At a glance
- Drugs Panobinostat (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 28 Jun 2018 Status changed from active, no longer recruiting to completed.
- 13 Oct 2017 Planned End Date changed from 1 Jan 2018 to 31 Dec 2018.
- 13 Oct 2017 Planned primary completion date changed from 1 Jan 2018 to 31 Dec 2018.